Introduction: A recombinant porcine factor VIII B-domain-deleted product (rpFVIII; OBIZUR, Baxalta Incorporated, Deerfield, IL 60015, USA) was recently approved for treatment of bleeding episodes in adults with acquired haemophilia A (AHA) in the United States. To date, no clinical experience outside the registration study has been reported. Aim: To describe early clinical experience using rpFVIII for AHA. Methods: A retrospective chart review of seven patients with AHA treated with rpFVIII at four institutions from November 2014 to October 2015. Results: The time to diagnosis of AHA ranged from 5 days to 6 weeks. Six major and one other bleed were treated with rpFVIII following unsatisfactory bypassing agent (BPA) therapy. Good haemostatic efficacy was seen in five of seven cases. rpFVIII loading doses of 100 (n = 6) or 200 U kg À1 (n = 1) increased FVIII activity from <1 to 9% at baseline to 109-650% within 0.25-7 h in six of seven cases. Subsequent median doses ranged from 30 to 100 U kg À1 for 3-26 days. No rpFVIII-related adverse events were reported. Three patients survived with inhibitor eradication, one with persistent inhibitor, two died with inhibitors present and one was discharged and later died from unrelated causes. Conclusions: rpFVIII showed good haemostatic efficacy with no recurrences in most cases, with consumption substantially less than in the registration study. Treatment decisions were based on FVIII activity levels and clinical assessment. The ability to titrate rpFVIII dose using FVIII activity was considered advantageous compared with BPA therapy. Notable delays in diagnosis were observed.
Introduction
Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibody-mediated neutralization of factor VIII (FVIII) activity [1] . The disorder affects predominantly elderly individuals in whom complicating comorbidities, including thrombogenic disorders, generally exist [1, 2] . Bleeding in patients with AHA who have high-titre inhibitors (≥5 Bethesda units [BU] mL À1 ) is managed with activated clotting factor(s) that bypass the need for FVIII for thrombin generation [3] . However, it is not possible to measure the activity levels of these bypassing agents (BPAs); thus, dosing is empirical and achieving precise control of clotting function is challenging [3] . Further, high-dose BPA therapy may be associated with thromboembolism (particularly in older patients) [3] and activation of coagulation 'downstream' from the ratelimiting intrinsic Xase may result in inferior haemostasis compared with replacement of the neutralized clotting factor.
Plasma-derived porcine FVIII (pd-pFVIII) was an alternative to BPAs introduced in 1986 but withdrawn in 2005, largely because of concerns regarding the potential for porcine parvovirus transmission. pd-pFVIII was, however, an efficacious treatment for the control of bleeding in patients with AHA. pdpFVIII differed sufficiently from human FVIII to be unrecognizable by circulating inhibitory anti-human FVIII (anti-hFVIII) antibodies, but was similar enough to result in human FVIII-like clotting function [4] . It was also possible to measure FVIII activity accurately using existing assays, allowing for more precise regulation of clotting function compared with BPAs [1] .
In late 2014, a recombinant porcine sequence FVIII B-domain-deleted product (rpFVIII) was approved in the United States [5] on the basis of a phase 2/3 registration study [6] . However, given the rarity of AHA, the available data on which to base treatment decisions was limited solely to this study. The trial included 28 patients who were selected using specific inclusion criteria and who received initial doses according to protocol, thereby impacting the generalizability of findings to clinical practice. Here, we describe the first reported clinical experience using rpFVIII for AHA.
Methods
A retrospective chart review of patients diagnosed with AHA and treated with rpFVIII between November 2014 and October 2015. Cases were included if the treating or supervising physician accepted an invitation to participate. A data collection form was developed for systematic retrieval of anonymized patient data; no identifying data or protected health information were collected. Local Institutional Review Board approval was obtained at those sites where it was required.
Results
Five physicians from four institutions agreed to participate in the case series, contributing a total of seven individual cases. Tables 1 and 2 summarize patient information and treatment. In all cases, initial treatment using BPAs and other haemostatic therapies had limited efficacy. The introduction of rpFVIII resulted in bleeding cessation within 24-48 h in four of seven cases and within 4 days in one case (Patient 7). In the remaining two cases (Patients 3 and 4), bleeding did not stop.
Summary description of cases
The mean total dose of rpFVIII administered per patient was 1230 U kg À1 (Table 3 ). rpFVIII loading doses of 100 U kg À1 (n = 6) or 200 U kg À1 (n = 1) increased FVIII activity from <1 to 9% to 109-650% within 0.25-7 h in all but one case (Patient 4). Subsequent rpFVIII doses ranged from 30 to 200 (median 30-100) U kg À1 (Table 3) , with corresponding FVIII activity levels between 7% and 224% where this information was available (Patients 1, 2, 3 and 7). FVIII activity began to decline in two patients after 26 and 8 days respectively (Patients 1 and 2). No adverse events associated with rpFVIII were observed, including any observations of thrombocytopenia or thromboembolism. AHA, acquired haemophilia A; aPCC, activated prothrombin complex concentrate; CT, computerized tomography; FVIII, factor VIII; N/A, not available; rFVIIa, recombinant activated factor VII; rFVIII, recombinant factor VIII; rpFVIII, recombinant porcine sequence factor VIII; pRBC, packed red blood cells. *Unknown -CT of neck demonstrated some improvement on day 10.
Patient 1: case summary
A 90-year-old man presented with gross haematuria at an emergency department (ED). A diagnosis of idiopathic AHA was made upon haematology consultation 14 days later (day 1). Treatment was focused on sufficient resolution of bleeding to allow the patient to return home to his family. The patient received recombinant factor VIIa (rFVIIa) for 18 days and methylprednisolone from day 2. Haematuria lessened but did not resolve completely; FVIII activity remained low (<9%). rpFVIII was initiated on day 20. The gross haematuria cleared within 48 h of the first rpFVIII dose (100 U kg
À1
) and FVIII activity increased to 140%. rpFVIII was continued at 40-50 U kg À1 every 8 h (q8 h) to every 12 h (q12 h) to prevent bleed recurrence until day 30, when the patient was discharged. During this period, FVIII activity levels were sustained between 37 and 95%. rpFVIII was continued on an outpatient basis at 50 U kg À1 q12 h, and then tapered to 50 U kg À1 every other day and discontinued on day 46 because of declining FVIII activity levels (indicative of anti-porcine FVIII [anti-pFVIII] antibody development; no titres available). rFVIIa was reinstituted to control intermittent bleeding. The patient died from causes unrelated to AHA on day 168.
Patient 2: case summary
A 24-year-old woman presented with severe intraabdominal bleeding and prolonged activated partial thromboplastin time (aPTT) 6 days following abdominal surgery. A diagnosis of AHA associated with exposure to ertapenem and intra-abdominal sepsis was made 4 days later (day 1). The patient received supportive transfusion and a series of haemostatic therapies including desmopressin, recombinant factor VIII (rFVIII), activated prothrombin complex concentrates (aPCC) and tranexamic acid from day 1 to 10. No substantial haemostatic benefit was observed.
rpFVIII was subsequently administered on days 10-17 at dosages of 100 U kg À1 intravenously (IV) once daily for 3 days, 100 U kg À1 q12 h for 3 days and 200 U kg À1 q8 h for 2 days. FVIII activity increased from 7 to 140% within 7 h of the first rpFVIII dose and acute bleeding ceased within 24 h. However, by day 18, FVIII activity was declining despite increasing doses of rpFVIII; anti-pFVIII antibodies were detected and no further rpFVIII was given.
A complete factor analysis at this time identified a consumptive FXIII deficiency (FXIII 8%; FXIII inhibitor analysis negative). aPCC was resumed with plasmaderived FXIII (pdFXIII) every 4 days. A massive intraabdominal bleed on day 27 was treated with aPCC, rFVIIa and plasma-derived von Willebrand factor:FVIII concentrate (pdVWF:FVIII). The patient was subsequently maintained on pdVWF:FVIII and pdFXIII. FVIII inhibitor eradication was pursued with daily prednisone from day 1 and weekly rituximab from day 8. All FVIII-related therapy was discontinued on day 37, at which time FVIII inhibitors were undetectable and endogenous FVIII activity was normal. FXIII levels subsequently normalized. D-dimer levels were persistently elevated throughout the treatment period.
Patient 3: case summary
A 78-year-old man with a 3-4 months history of recurrent gastrointestinal (GI) bleeding was readmitted with an acute GI bleed. A carcinoid tumour in the small bowel was identified and surgically resected. The patient continued to bleed postoperatively and was diagnosed with AHA 10 days later (FVIII activity <1%; day 1), possibly associated with the tumour. rFVIIa was administered during days 6-17 and 39-40, as well as aPCC on days 17-24, 27-35 and 39, with no resolution of bleeding. Corticosteroids were initiated on day 1, augmented with intermittent doses of rituximab and cyclophosphamide.
rpFVIII 100 U kg À1 was administered on day 40, and FVIII activity increased from <1 to 650% within 30 min. Therapy was continued until day 57 at doses ranging from 30 to 100 U kg À1 (Table 3) and FVIII activity levels were sustained at 37-224%. However, bleeding continued and the patient developed sepsis, expiring on day 57 without evidence of inhibitor eradication. Haemophilia (2017), 23, 25--32
Patient 4: case summary
An 83-year-old man with a 6-week history of prolonged aPTT presented with a spontaneous, severe retropharyngeal bleed that compromised the airway and required intubation. The patient was diagnosed with idiopathic AHA (day 1; FVIII activity <1%).
Haemostatic treatment was initiated with aPCC. After 5 days with no substantial improvement, treatment was switched to rpFVIII with a loading dose of 100 U kg À1 and subsequent doses of 50-100 U kg
À1
. rpFVIII was discontinued after 3 days because no meaningful effect on FVIII activity was observed. An anti-pFVIII titre of 2 BU was detected in plasma collected from the patient on day 1. aPCC was subsequently resumed, but the patient did not recover consciousness following extubation and expired soon thereafter. Inhibitor eradication was not attempted. D-dimer levels were elevated during rpFVIII treatment.
Patient 5: case summary
A 56-year-old woman presented at her primary care office with a left forearm intramuscular haemorrhage of moderate severity. She was subsequently hospitalized and diagnosed with AHA associated with osteomyelitis 17 days later (day 1). The patient received rFVIIa for 5 days, with tranexamic acid during the first 48 h.
Continued bleeding and a history of deep vein thrombosis prompted initiation of rpFVIII on day 6 at a loading dose of 100 U kg
À1
. FVIII activity increased from <1 to 192% (Fig. 1a) and bleeding ceased by the next day. rpFVIII was continued at 50 U kg À1 q12 h for 4 days, then 50 U kg À1 daily for another 19 days to prevent recurrence or new bleeds. The patient was discharged on day 13, with no subsequent bleeding reported. Immunosuppressive therapy was initiated on day 1 with daily prednisone, with daily cyclophosphamide from day 2 and weekly rituximab from day 7. Inhibitor eradication was inferred from normalized FVIII activity from day 29 onward.
Patient 6: case summary
An 83-year-old male presented to an ED with severe haematuria and coffee-ground emesis secondary to prostate/bladder bleeding and a Mallory-Weiss tear respectively. A diagnosis of AHA associated with underlying prostate cancer was made 15 days later (day 1). Treatment with rFVIIa was commenced but discontinued after 3 days because of ongoing bleeding.
rpFVIII was initiated on day 3 with a loading dose of 200 U kg
À1
. FVIII activity increased from 2 to 438% (Fig. 1b) and bleeding ceased within hours. The patient received rpFVIII 50 U kg À1 three times daily for 2 days, after which it was discontinued because bleeding had resolved and FVIII activity levels had normalized. Immunosuppression was achieved with prednisone, rituximab and dexamethasone. Inhibitor eradication was inferred from multiple FVIII activity levels >100% from day 7 onwards.
Patient 7: case summary
A 64-year-old man presented at an ED with a major intramuscular bleed of the left arm requiring transfusion of four units of red blood cells. Five days later, the patient was diagnosed with idiopathic AHA (day 1). rFVIIa therapy was administered for 4 days, but bleeding persisted. rpFVIII 100 U kg À1 was administered on day 4 and FVIII activity increased from 10 to 109% within 1 h. Bleeding ceased within 4 days, associated with increased mobility of the limb and decreased oedema. An additional dose of rpFVIII 100 U kg À1 was given on day 7 and the patient was discharged. rpFVIII 100 U kg À1 day À1 was administered from days 9 to 14 in the outpatient clinic. No bleeding recurrences were observed. Inhibitor eradication was attempted with cyclophosphamide and prednisone, but not achieved at the time of manuscript acceptance. 
Discussion
We presented seven cases of AHA treated with rpFVIII following unsatisfactory response to BPA therapy with or without other haemostatic treatments. Good haemostatic efficacy was observed in five of the seven cases and no adverse events related to rpFVIII were observed. Consumption of rpFVIII was considerably less than that observed in the registration study [6] . These observations provide some justification for the consideration of rpFVIII as an option for first-line haemostatic treatment. The patients presented in a variety of locations. Although diagnosis of AHA in each case occurred on the same day as haematology consultation, the time from presentation until such consultation ranged from 5 days to 6 weeks. Five of seven cases (71%) had a delay in diagnosis of more than 1 week, and one (Patient 3) had a 3-4-month history of a recurrent GI bleed, potentially indicating an even longer delay. This proportion of cases with a delay of more than 1 week to diagnosis is larger than the 36.7% described in the European Acquired Haemophilia (EACH2) registry [2] . In this registry, delayed diagnosis and treatment was not associated with overall survival [2] , but a delayed time to treatment was associated with reduced responsiveness to treatment [7] . Therefore, the observed delay in diagnosis may have influenced the lack of response to treatment in Patients 3 and 4.
In six of seven cases, the loading dose of rpFVIII was 100 U kg
À1
, compared with 200 U kg À1 in the registration trial [6] . Our findings suggest that an initial loading dose of 100 U kg À1 may be sufficient to achieve normal measured FVIII activity in most patients. Subsequent median doses per infusion in our cases (30-100 U kg À1 ) (Table 3) were also substantially less than in the approval study [6] , where the median dose per infusion for all subjects was 133 U kg
. The mean total dose administered per patient in this series was 1230 U kg
, compared with 3123 U kg À1 in the approval study [6] . The ability to titrate rpFVIII doses using FVIII activity levels was considered an advantage over BPAs. The inability to measure activity of rFVIIa contributed to underdosing in Patients 5 and 6 because of concerns about the risk of thrombosis. Cautious dosing of BPAs in this predominantly frail elderly population, while understandable, may be insufficient to obtain therapeutic effects. The normalization of FVIII activity by rpFVIII did decline in two cases (Patients 1 and 2) (Fig. 2a,b) , thought to be associated with the development of anti-pFVIII antibodies. Anti-hFVIII antibody titres also increased during rpFVIII treatment in Patient 2, suggesting cross-reactivity.
In two patients (Patients 3 and 4), no clinical response to rpFVIII was observed. In Patient 3, the surgical wound or other undiagnosed coagulopathy may have contributed to a poor outcome despite a robust and sustained increase in FVIII activity (Fig. 2c) . Patient 4 showed little increase in FVIII activity, raising the possibility of cross-reactivity of anti-hFVIII antibodies to rpFVIII. Both patients had significant anti-hFVIII antibody titres at initial consultation (205 and 374 BU respectively) and Patient 4 had an anti-pFVIII titre of 2 BU mL À1 at the commencement of rpFVIII therapy. Five of 28 patients in the pivotal rpFVIII study [6] developed de novo antipFVIII antibodies and bleed control was not considered successful in two of them. In this case series, repeated anti-pFVIII antibody testing during therapy was only performed for a single patient (Patient 2). FVIII activity levels were measured 1-6 times a day, at different times each day and also with respect to rpFVIII dose. For those days with more than one measurement, the lowest was used in the figure.
This assisted treatment planning, given the expectation that rpFVIII treatment responsiveness would continue to wane. Overall, however, treatment decisions across the seven cases were based predominantly on FVIII activity levels and clinical assessment. Anti-hFVIII antibody titres were also not universally collected throughout these cases, and in two cases (Patients 5 and 6), eradication was inferred on the basis of FVIII activity.
No rpFVIII-related adverse events were observed in any of the cases, which is consistent with the results of the pivotal study [6] . There were no signs of thrombocytopenia in our cases or in the registration study [6] , although this was a common complication of pdpFVIII [8] . No clinical signs of thrombosis were observed in the present series, but D-dimer levels were elevated in the two patients in whom this was monitored.
AHA was considered idiopathic in three cases, associated with ertapenem exposure and sepsis in Patient 2 and with osteomyelitis and prostate cancer in Patients 5 and 6, respectively, and possibly associated with a carcinoid tumour in Patient 3. In the EACH2 registry, AHA was associated with drug exposure in 3.4%, infections in 3.8% and malignancies of any type in 11.8% of cases [2] . These cases highlight the varied presentation of AHA, emphasizing the need for an individualized approach to therapy. The clinical course of Patient 2 was complicated by a concomitant FXIII deficiency, highlighting the need to consider other haemostatic defects if bleeding persists despite targeted treatment of AHA. Patient 1 received limited immunosuppressive therapy to eradicate the inhibitor because of concerns over possible toxicity and infection; instead, treatment was focused on bleeding resolution to allow the patient to return home. In Patient 6, inhibitor eradication was achieved with a regimen of dexamethasone and rituximab, in an attempt to reduce the psychiatric effects of prolonged prednisone administration.
Our patients are likely more representative of realworld clinical experience than subjects recruited for the clinical trial [6] , who were subject to certain inclusion criteria and in whom loading doses were per-protocol. Cases were included irrespective of the clinical presentation or outcome. These cases represent the first description of the clinical use of rpFVIII for AHA outside of a clinical trial.
Cases were included on the basis of acceptance by the physician of an invitation to participate and, as such, represent a self-selected subset of the total experience to date. Consequently, our observations and conclusions may not be generalizable to all treatment experiences or future cases. Repeated anti-pFVIII antibody titres during rpFVIII therapy were available in only one of the included cases, precluding any comment on their incidence or effect on therapy in clinical practice.
Conclusions
rpFVIII was administered following unsatisfactory responses to BPA or other haemostatic therapies and resulted in rapid bleeding cessation with no recurrences in the majority of cases. Loading doses and median subsequent doses of rpFVIII were substantially less than those reported in the registration study [6] . rpFVIII was not effective in all cases, and in three patients, there was evidence of anti-pFVIII or crossreactive anti-hFVIII antibodies; this prompted withdrawal of rpFVIII in one case.
Treatment decisions were principally based on FVIII activity levels and clinical response. The ability to measure FVIII activity and to adjust treatment accordingly was considered advantageous compared with BPA therapy, where treatment decisions were made empirically and dosing was constrained in some cases by a perceived risk of thromboembolism. There was considerable variability across these seven real-world cases regarding dosing of rpFVIII, immunosuppressive therapy and laboratory monitoring. Given this clinical heterogeneity and complexity, we recommend that patients are treated at a Hemophilia Treatment Center (HTC) if at all possible.
Finally, these cases were notable for significant delay in the diagnosis of AHA, which may have affected treatment effectiveness in some cases. Although the effect of these delays on final outcomes is uncertain, they represent a potentially avoidable prolongation of patient morbidity and increase in healthcare resource utilization.
